Lawrenceville, NJ, United States of America

Michael J Sofia

This inventor holds 20 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Eli Lilly and Company, E. R. Squibb Sons, Inc., Transcell Technologies, Inc.. Active years: 1992-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael J Sofia. Retrieved from https://idiyas.com/inventor/michael-j-sofia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 231(Granted Patents)

Location History:

Carmel, IN (US) (1993 - 1996)
Laurenceville, NJ (US) (1997)
Lawrenceville, NJ (US) (1992 - 2001)

Company Filing History:

6 out of 4,517

Eli Lilly and Company

patents

4 out of 1,624

E. R. Squibb Sons, Inc.

patents

4 out of 5

Transcell Technologies, Inc.

patents

4. 2 out of 2

Incara Research Laboratories

Advanced Medicine, Inc.

8. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2001

Loading Chart...

Areas of Expertise:

Moenomycin Analogs

Polyamine Conjugates

Glycosylated Bile

Phospholipase A2 Inhibitors

Leukotriene Antagonists

Steroid Derivatives

HMG-CoA Reductase Inhibitors

Squalene Synthetase Inhibitors

3-Amino-Substituted Compounds

Biological Transport

Alzheimer's Disease Treatment

Process Manufacturing

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6274716 - Combinatorial library of moenomycin analogs and methods of producing same (2001-08-14),

2. 6207820 - Combinatorial library of moenomycin analogs and methods of producing same (2001-03-27),

3. 6114309 - Combinatorial library of moenomycin analogs and methods of producing same (2000-09-05),

4. 6017906 - Polyamine conjugates for treatment of infection (2000-01-25),

5. 5864022 - Process for the manufacture of 3-amino-substituted glycosylated bile (1999-01-26),

6. 5744453 - Polyamine conjugates for treatment of infection (1998-04-28),

7. 5731423 - Process for preparing sulfoxides (1998-03-24),

8. 5693770 - Process for the manufacture of 3-amino-substituted glycosylated bile (1997-12-02),

9. 5627270 - Glycosylated steroid derivatives for transport across biological (1997-05-06),

10. 5585470 - Process for the manufacture of 3-amino-substituted glycosylated bile (1996-12-17),

11. 5563164 - Phospholipase A.sub.2 inhibitors (1996-10-08),

12. 5552441 - Leukotriene B4 antagonists (1996-09-03),

13. 5478857 - Use of PLA.sub.2 inhibitors as treatment for alzheimer's disease (1995-12-26),

14. 5462954 - Substituted phenyl phenol leukotriene antagonists (1995-10-31),

15. 5352690 - 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists (1994-10-04),

Title: Michael J. Sofia: Pioneer in Antibiotic Research and Innovation

Introduction: Michael J. Sofia is an accomplished inventor based in Lawrenceville, NJ, USA, known for his significant contributions to the field of antibiotic research. With an impressive portfolio of 20 patents, Sofia has been at the forefront of innovative solutions in medicinal chemistry, particularly in the development of new antibiotic compounds.

Latest Patents: One of Sofia's notable recent patents is titled "Combinatorial Library of Moenomycin Analogs and Methods of Producing Same." This patent pertains to a combinatorial chemical library comprised of compounds that are structurally related to the moenomycin class of antibiotics. The methodology outlined in this patent offers techniques for producing these analogs, which may lead to advancements in antibiotic development.

Career Highlights: Throughout his career, Michael J. Sofia has made substantial strides while working at renowned pharmaceutical companies such as Eli Lilly and Company and E.R. Squibb & Sons, Inc. His expertise has helped shape the direction of research in the pharmaceutical industry, particularly in the quest for new and effective antibiotics.

Collaborations: Sofia has collaborated with several distinguished colleagues, including Ramesh Kakarla and Dashan Liu. These partnerships have enhanced the research endeavors within his projects and contributed to the successful development of new pharmacological compounds.

Conclusion: Michael J. Sofia's contributions to antibiotic research demonstrate his innovative spirit and commitment to advancing medical science. With a strong foundation of patents and collaborations, his work continues to influence the future of antibiotic development and therapeutic solutions.

Profile summary based on public USPTO records.